MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million

January 2, 2024

https://www.globenewswire.com/news-release/2024/01/02/2802534/29517/en/MannKind-and-Sagard-Healthcare-Enter-Into-Royalty-Purchase-Agreement-for-Up-to-200-Million.html

WESTLAKE VILLAGE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq:MNKD) announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.

Read more at globenewswire.com

Related news for (MNKD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.